Meeting
2020 Genitourinary Cancers Symposium
Phase III study of perioperative pembrolizumab (pembro) plus cystectomy versus cystectomy alone in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-905.
Authors
Matt D. Galsky
Icahn School of Medicine at Mount Sinai, New York, NY
Matt D. Galsky , Andrea Necchi , Neal D. Shore , Fred Witjes , Kijoeng Nam , Eric Sbar , Blanca Homet Moreno , Elizabeth R. Plimack
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Adrenal Cancer,Penile Cancer,Prostate Cancer - Advanced,Prostate Cancer - Localized,Testicular Cancer,Urethral Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03924895
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr TPS593)
Abstract #
TPS593
Poster Bd #
N11
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
KEYNOTE-905/EV-303: Perioperative pembrolizumab or pembrolizumab plus enfortumab vedotin (EV) and cystectomy compared to cystectomy alone in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC).
First Author: Matt D. Galsky
Poster
2019 ASCO Annual Meeting
DUTRENEO Trial: A phase II randomized trial of DUrvalumab and TREmelimumab as NEOadjuvant approach in muscle-invasive urothelial bladder cancer (MIBC) patients prospectively selected by immune signature scores.
First Author: Enrique Grande
Poster
2021 ASCO Annual Meeting
KEYNOTE-B15/EV-304: Randomized phase 3 study of perioperative enfortumab vedotin plus pembrolizumab versus chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC).
First Author: Christopher J. Hoimes
Poster
2020 Genitourinary Cancers Symposium
Phase III study of perioperative pembrolizumab (pembro) plus neoadjuvant chemotherapy (chemo) versus placebo plus neoadjuvant chemo in cisplatin-eligible patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-866.
First Author: Arlene O. Siefker-Radtke